Who should NOT buy red light therapy (yet)
Verdict: If you're shopping for testosterone, thyroid, weight loss, or because you think a higher‑power panel is automatically better — don't buy yet.
We publish don’t‑buy verdicts because our content rules require them (ev041). A systematic who‑should‑NOT‑buy page is a lane nobody in this industry serves (ev036). Most condition‑farms conclude “buy a panel” in every cell (ev037). We don’t.
---
1. The contract: why this page exists
The red‑light‑therapy industry is full of pages that start with “red light therapy helps with X” and end with a buy button — regardless of whether the evidence supports X. That’s the Mad Libs pattern (ev037). Our content rules demand the opposite: when the evidence is thin, we say “don’t buy for this” (ev041). A dedicated who‑should‑NOT‑buy page is an unserved white‑space lane (ev036). This is that lane.
---
2. Where the evidence is real vs. where the marketing is loud
The academic literature on photobiomodulation is large and uneven — stronger for some dermatology and pain endpoints, thin for many consumer‑marketed uses (ev005). There’s a claim/evidence inversion: the best‑evidenced uses (dermatology, some pain endpoints) are not the loudest‑marketed ones (testosterone, thyroid, weight loss) (ev016). We copy the hedged phrasing of the evidence pool — never upgrade confidence (VF1).
What the evidence supports (honest, tiered answer):
- The literature is stronger for some dermatology endpoints and some pain endpoints — that is the top of the tier list (ev005).
- It is thin for many of the uses consumer marketing leans on (ev005).
- Per-condition verdicts need per-condition evidence — those pages are the follow-on work (ev041). Until they exist, we don't name condition-level winners here.
What the marketing shouts: testosterone, thyroid, weight loss. These sit on the thin end of the inversion (ev016). The literature does not support buying a device for these goals at current evidence levels.
---
3. Don’t buy FOR these goals
- Testosterone, thyroid, weight loss — the evidence is thin. The loudest‑marketed uses are not the best‑evidenced ones (ev016). If that’s your primary goal, don’t buy yet.
- Wavelength‑superiority shopping — the debate over 660 vs. 630 nm, 850 vs. 810 nm, or multi‑band value is permanently unresolved; head‑to‑head consumer evidence does not exist (ev011). Pulsed vs. continuous output is marketed as a premium differentiator while the comparative evidence is unsettled (ev012). Don’t buy a panel because it claims “better wavelengths” — that’s not a supported reason.
---
4. Wait, don’t buy if…
- You cannot commit to consistent use across the realistic ~8‑12‑week horizon. The weeks‑3‑8 doubt window is where buyers churn (ev033). If you’re not willing to use it daily or near‑daily for two to three months before judging results, wait.
- You expect a wellness device to address an undiagnosed condition. Most consumer RLT devices ship under FDA’s general‑wellness enforcement‑discretion policy — no clearance required if claims stay at wellness level (ev006). A subset of devices carry 510(k) clearances for specific indications (e.g., some Omnilux, iRestore, Kineon predicates), but that’s the exception, not the default (ev007). If you have an undiagnosed medical issue, see a clinician — don’t buy a panel.
- You’re shopping because you think more power = more benefit. The biphasic dose response (“less is more” beyond a threshold) is a recurring theme in the PBM literature and contradicts the “more power” spec war (ev013). Doses in the literature are ranges, never points (ev019). More power and more minutes are not more benefit.
Not medical advice. This is a buying‑guide verdict. If you have a medical condition, consult a qualified healthcare provider before purchasing any light‑therapy device.
---
5. Fine to buy if you know what you’re buying
If you go in with wellness‑level expectations and the biphasic reality in view, a panel can be a reasonable purchase. You’re buying a wellness tool, not a cleared medical treatment. The literature shows effective doses in the ~3‑60 J/cm² range at tissue surface depending on target — no single agreed number exists (ev019). More power and more minutes are not more benefit (ev013). A panel that Light Therapy Insiders measured at 55 mW/cm² [measured] panel average (ev051 — the reviewer’s dosing math is framed at ~6 inches; the exact test distance isn’t stated beside the figure) is a known quantity; a panel claiming 150 mW/cm² [claimed] isn’t necessarily better — brands publish peak‑spot or close‑distance numbers, and independent testers often measure well below the claim (ev010). Buy for the measured average, not the peak claim.
---
6. What buyers themselves report
Dosing confusion (how long, how far, how often) dominates post‑purchase questions (ev028). Buyers assume deception by default — “marketing fluff,” spec‑transparency distrust, assumed reviewer sponsorship (ev030). We cite these as what buyers ask, never as evidence the therapy works or fails (community‑tier rule). The community’s signature posture is double‑consciousness: hopeful believers who self‑police placebo (“Not sure if placebo but…”) (ev031). That posture is respected, never mocked.
---
7. What would change our answer
- Per‑condition evidence pages with tiered verdicts (matrix C, ev041) — if a condition we currently say “don’t buy for this” gains stronger evidence, we’ll update the verdict.
- Named 510(k) clearances — we verify each clearance against the FDA database before naming a device as cleared (ev007). If a device you’re considering has a verified 510(k) for your specific indication, that changes the calculus.
Until then, the honest verdict for testosterone, thyroid, weight loss, wavelength‑shopping, and “more power” shopping is: don’t buy yet.